Developing global, high-value products for patients with significant unmet medical needs in niche indications
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
Calliditas shortlisted for the Capital Market Transaction of the Year at the European Mediscience Awards.
On August 15, 2019, Calliditas Therapeutics published its business update for the second quarter 2019.
Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Company number: 556659-9766
© Calliditas Therapeutics AB 2019